Substantial changes foreseen in anti-hypertension drug markets.
Published: 2004-10-18 06:59:00
Updated: 2004-10-18 06:59:00
Daewoong may introduce Olmetec, a new anti-hypertension drug, an angiotensin II receptor blocker, next year after its health registration completing in Oct. this year, which seems to cause a big change in the anti-hypertension drug markets.
Considering excellent therapeutic profiles of Olmete...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
